фильм неслужебное задание все серии скачать торрент
Главное меню:
Интересное
фильм неслужебное задание все серии скачать торрент, Epidemiology of metastatic hepatocellular carcinoma, a nationwide , Treatment for Advanced Hepatocellular Carcinoma: Current Standard and , Current Treatment Paradigm and Approach to Advanced Hepatocellular , Treatment strategies for locally advanced hepatocellular carcinoma, Hepatocellular Carcinoma: Consensus Recommendations of the National , Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline , Clinical Characteristics, Treatment Patterns, and Outcomes of Patients .
We included 25,671 and 26,054 HCC patients from UHC and NIS, respectively. Prevalence of metastatic HCC was 18 % with lung being the most frequent site (31 %). Compared with Caucasian, African American ethnicity was an independent predictor of metastasis in both the NIS [OR 1.13 (1.02-1.25)] and UHC [OR 1.4 (1.3-1.6)] databases. Lack of long-term insurance was associated with significantly higher prevalence of metastasis in both the NIS [OR 1.6 (1.4-1.9)] and UHC [OR 1.9 (1.6-2.2)] databases. There has been an increased prevalence of metastatic HCC over the last decade with an annual percentage change of +1.25 and +1.60 % (p = 0.03 and p = 0.08) for the NIS and UHC databases, respectively., Results: We included 25,671 and 26,054 HCC patients from UHC and NIS, respectively. Prevalence of metastatic HCC was 18 % with lung being the most frequent site (31 %). Compared with Caucasian, African American ethnicity was an independent predictor of metastasis in both the NIS [OR 1.13 (1.02-1.25)] and UHC [OR 1.4 (1.3-1.6)] databases., Although staging systems vary, parameters that define advanced stage HCC eligible for therapy include presence of portal vein tumor invasion and/or extrahepatic metastases, with relatively preserved liver function and functional status..
The BRIDGE study highlighted that over 50% of patients diagnosed with HCC were in advanced or terminal stages, with even higher proportions in limited-resource countries [4]. A considerable number of advanced-stage HCC patients are unfortunately unsuitable for liver resection surgery or local treatment, thus limiting many management options., Patients with advanced tumors can be candidates for multiple therapies, ranging from potentially curative options such as transplantation and resection—to locoregional and systemic treatments; these should be evaluated on an individual basis by a multidisciplinary team., At present, only one chemotherapeutic agent is approved for advanced HCC patients. This large majority of HCC patients represents a significant unmet medical need for more effective systemic therapy options., To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC). ASCO convened an Expert Panel to update the 2020 guideline on systemic therapy for HCC., Multiple options exist for first-line treatment of metastatic HCC. Before 2008, there were few options for the treatment of HCC; however, in 2008, the first tyrosine kinase inhibitor (TKI), sorafenib, was introduced and approved by the Food and Drug Administration (FDA) based on the SHARP trial, which demonstrated survival benefits. 1., Results: A total of 586 patients with advanced/ metastatic HCC were identified in the database. 330 patients received 1L therapy, and of those patients 63% (N= 207) received systemic 2L therapy (n= 105) or SCA (n= 102)..